BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37997497)

  • 21. Characterization of a cuproptosis-related signature to evaluate immune features and predict prognosis in colorectal cancer.
    Li L; Sun F; Kong F; Feng Y; Song Y; Du Y; Liu F; Kong X
    Front Oncol; 2023; 13():1083956. PubMed ID: 37384293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive analysis of the role of cuproptosis-related genes in the prognosis and immune infiltration of adrenocortical Carcinoma.
    You Z; He J; Gao Z
    Heliyon; 2024 Jan; 10(1):e23661. PubMed ID: 38187219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cuproptosis-related gene signature and associated regulatory axis in stomach adenocarcinoma based on bioinformatics analysis.
    Ding D; Wang D; Qin Y
    Medicine (Baltimore); 2023 Jul; 102(30):e34230. PubMed ID: 37505170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crosstalk of cuproptosis-related prognostic signature and competing endogenous RNAs regulation in hepatocellular carcinoma.
    Zhu J; Wang J; Liu H; Lei T; Yang J; Lan S; Jian H; Fang H; Zhang Y; Ren K; Zhong F
    Aging (Albany NY); 2023 Dec; 15(23):13901-13919. PubMed ID: 38078880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
    Chen X; Hu G; Xiong L; Xu Q
    Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical significance and potential application of cuproptosis-related genes in gastric cancer.
    Yan JN; Guo LH; Zhu DP; Ye GL; Shao YF; Zhou HX
    World J Gastrointest Oncol; 2023 Jul; 15(7):1200-1214. PubMed ID: 37546553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and validation of a novel cuproptosis-related genes signature associated with prognosis, clinical implications and immunotherapy of hepatocellular carcinoma.
    He F; Zeng P; Ma S; Yang X; Liu H; Liu Q; Zhou Y; Zhu H
    Front Pharmacol; 2023; 14():1088993. PubMed ID: 36843949
    [No Abstract]   [Full Text] [Related]  

  • 28. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
    Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
    Front Immunol; 2022; 13():919231. PubMed ID: 35967366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic and immune correlation evaluation of a novel cuproptosis-related genes signature in hepatocellular carcinoma.
    Zhou Z; Zhou Y; Liu D; Yang Q; Tang M; Liu W
    Front Pharmacol; 2022; 13():1074123. PubMed ID: 36588699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of cuproptosis identified immune microenvironment and prognosis in acute myeloid leukemia.
    Luo D; Liu S; Luo J; Chen H; He Z; Gao Z; Wen Z; Liu X; Xu N
    Clin Transl Oncol; 2023 Aug; 25(8):2393-2407. PubMed ID: 36826709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
    Zhang X; Ye Z; Xiao G; He T
    Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cuproptosis related genes signature predicts the prognosis and correlates with the immune status of clear cell renal cell carcinoma.
    Sun P; Xu H; Zhu K; Li M; Han R; Shen J; Xia X; Chen X; Fei G; Zhou S; Wang R
    Front Genet; 2022; 13():1061382. PubMed ID: 36531222
    [No Abstract]   [Full Text] [Related]  

  • 33. Regulation, genomics, and clinical characteristics of cuproptosis regulators in pan-cancer.
    Zhou C; Li C; Zheng Y; Huang X
    Front Oncol; 2022; 12():934076. PubMed ID: 36387247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Machine learning-based solution reveals cuproptosis features in inflammatory bowel disease.
    Liu L; Liang L; Yang C; Chen Y
    Front Immunol; 2023; 14():1136991. PubMed ID: 37275904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and validation of cuproptosis-related lncRNAs associated with pancreatic cancer immune microenvironment based on single-cell.
    Sun Y; Yao L; Man C; Gao Z; He R; Fan Y
    Front Immunol; 2023; 14():1220760. PubMed ID: 37822927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Construction of Lung Adenocarcinoma Prognosis Model and Drug Sensitivity Analysis Based on Cuproptosis Related Genes].
    Sun J; Zhang H; Liu H; Dong Y; Wang P
    Zhongguo Fei Ai Za Zhi; 2023 Aug; 26(8):591-604. PubMed ID: 37752539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cuproptosis-related prognostic signatures predict the prognosis and immunotherapy in HCC patients.
    Peng H; Zou Z; Xiang Z; Lu X; Zhang Y; Peng X
    Medicine (Baltimore); 2023 Aug; 102(34):e34741. PubMed ID: 37653738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma.
    Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
    Front Genet; 2023; 14():1056000. PubMed ID: 36845390
    [No Abstract]   [Full Text] [Related]  

  • 40. Insights into prognosis and immune infiltration of cuproptosis-related genes in breast cancer.
    Huang T; Liu Y; Li J; Shi B; Shan Z; Shi Z; Yang Z
    Front Immunol; 2022; 13():1054305. PubMed ID: 36518756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.